Benecchi Christopher 4
4 · Sage Therapeutics, Inc. · Filed Nov 14, 2024
Insider Transaction Report
Form 4
Benecchi Christopher
Chief Operating Officer
Transactions
- Award
Stock Option (Right to buy)
2024-11-01+12,500→ 12,500 totalExercise: $6.05Exp: 2034-11-01→ Common Stock (12,500 underlying) - Award
Common Stock
2024-11-01+6,250→ 24,737 total
Footnotes (2)
- [F1]Consists of shares of common stock issuable under 6,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on November 1, 2025, subject to the Reporting Person's continued service.
- [F2]The option was granted on November 1, 2024 pursuant to the Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on November 1, 2025, and the remainder vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.